33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Extracellular matrix (ECM) biomarkers are elevated in advanced renal cell carcinoma (aRCC) and predictive of response to nivolumab plus ipilimumab (NIVO+IPI): Analysis from CheckMate 214
    Meeting Abstract

    Gupta, S.; Han, C.; Dwivedi, B.; Li, J.; Karsdal, M.; Motzer, R.; Willumsen, N.; McDermott, D.; Choueiri, T.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Biomarker correlates of clinical response with FLT3L/nivo backbone treatment in the multi-cohort phase 1 porter platform trial in metastatic castration-resistant prostate cancer patients
    Meeting Abstract

    Shotts, K.; Howes, T.; Yu, J.; Densmore, J.; Da Silva, D.; Kumar, D.; Santulli-Marotto, S.; Cabanski, C.; Eisenbeisz, E.; Ivison, G.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Characteristics of the tumor microenvironment in IDH1-mutated cholangiocarcinoma patients from ClarIDHy trial
    Meeting Abstract

    Saatcioglu, H. D.; Valle, J.; Macarulla, T.; Javle, M.; Oh, D. Y.; Goyal, L.; Conway, J.; Iyer, J.; Najdawi, F.; Shah, C.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Clinical and pharmacodynamic biomarker results from porter, a multi-cohort phase 1 platform trial of combination immunotherapy for metastatic castration-resistant prostate cancer patients
    Meeting Abstract

    Galsky, M.; Autio, K.; Wentzel, K.; Graff, J.; Friedlander, T.; Densmore, J.; Cabanski, C.; Shotts, K.; Howes, T.; Yu, J.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Small cell lung cancer molecular subtypes and vulnerability to immune checkpoint blockade
    Meeting Abstract

    Nabet, B.; Hamidi, H.; Banchereau, R.; Morris, S.; Adler, L.; Srivastava, M.; Patil, N.; Gay, C.; Minna, J.; Heymach, J.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Generalizability of predictive versus prognostic indicators from published transcriptomic associations with tumor response to immune checkpoint inhibition
    Meeting Abstract

    Bortone, D.; Monette, A.; Tschernia, N.; Cogdill, A.; Najjar, Y.; Sweis, R. F.; Valpione, S.; Wennerberg, E.; Bommareddy, P.; Haymaker, C.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Cytotoxic revival is implicated in response to neoadjuvant PD-1 blockade for head and neck squamous cell carcinoma
    Meeting Abstract

    Afeyan, A.; Oliveira, G.; Egloff, A. M.; Zeng, Z.; Chernock, R.; Zhou, L.; Messier, C.; Lizotte, P.; Wolff, J.; Pfaff, K.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of immune checkpoint inhibitors (ICI) in patients living with HIV (PLWH) and metastatic non-small cell lung cancer (NSCLC): A matched cohort study from the International Catch-It Consortium
    Meeting Abstract

    El Zarif, T.; Nassar, A.; Adib, E.; Fitzgerald, B.; Huang, J.; Mouhieddine, T.; Nonato, T.; McKay, R.; Li, M.; Mittra, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Development of optimized car T cells for therapy of glioblastoma
    Meeting Abstract

    Khan, J.; Cai, W.; Yang, Y.; Dong, L.; Hopland, K.; Yu, K. K. H.; Freeman, R.; Purdon, T.; Tabar, V.; Merghoub, T.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Immunometabolic modulation of engineered iPSC-NK cells for immunotherapy of solid tumors
    Meeting Abstract

    Borde, S.; Matosevic, S.; Lupo, K.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save